Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vinorelbine + plerixafor
- Development stage
- Unknown
- Lead developer
- Pierre Fabre
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
Combination of vinorelbine (a chemotherapy agent) and plerixafor (a CXCR4 antagonist) used for stem cell mobilization, particularly in patients with multiple myeloma. This combination helps mobilize hematopoietic stem cells from the bone marrow into peripheral blood for collection and subsequent autologous transplantation. When combined with granulocyte-colony stimulating factor (G-CSF), the triple combination (VGP) has shown superior efficacy in mobilizing peripheral stem and progenitor cells compared to double combinations.
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)
Beyond the preview
Go deeper on vinorelbine + plerixafor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vinorelbine + plerixafor.